Hoth Therapeutics (NASDAQ:HOTH) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Hoth Therapeutics (NASDAQ:HOTH) posted its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01), Zacks reports.

Hoth Therapeutics Trading Down 7.1 %

HOTH stock traded down $0.06 during mid-day trading on Friday, hitting $0.79. 127,987 shares of the company were exchanged, compared to its average volume of 1,389,126. The business has a fifty day simple moving average of $0.92 and a 200-day simple moving average of $0.93. Hoth Therapeutics has a 12-month low of $0.58 and a 12-month high of $1.73.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HOTH. HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Hoth Therapeutics in a report on Monday, November 4th. Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 target price on shares of Hoth Therapeutics in a research note on Friday, October 11th. Finally, EF Hutton Acquisition Co. I raised shares of Hoth Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 21st.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.